Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Achieve Life Sciences (ACHV) Capital Expenditures (2016 - 2023)

Achieve Life Sciences (ACHV) has disclosed Capital Expenditures for 12 consecutive years, with $6000.0 as the latest value for Q4 2023.

  • Quarterly Capital Expenditures changed N/A to $6000.0 in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $21000.0 through Dec 2023, changed N/A year-over-year, with the annual reading at $3000.0 for FY2025, N/A changed from the prior year.
  • Capital Expenditures for Q4 2023 was $6000.0 at Achieve Life Sciences, up from $3000.0 in the prior quarter.
  • The five-year high for Capital Expenditures was $54000.0 in Q1 2019, with the low at -$2000.0 in Q2 2019.
  • Average Capital Expenditures over 3 years is $10857.1, with a median of $3000.0 recorded in 2020.
  • The widest YoY moves for Capital Expenditures: up 700.0% in 2020, down 96.3% in 2020.
  • Achieve Life Sciences' Capital Expenditures stood at $1000.0 in 2019, then surged by 200.0% to $3000.0 in 2020, then surged by 100.0% to $6000.0 in 2023.
  • Per Business Quant, the three most recent readings for ACHV's Capital Expenditures are $6000.0 (Q4 2023), $3000.0 (Q3 2020), and $12000.0 (Q2 2020).